Clare Hague, EMEA Therapeutic Area Market Access Leader at Janssen, was featured in The Evidence Base’s RWE in Pharma series last year. Hague laid out the growing role of real-world data and evidence (RWD, RWE) in the pharmaceutical industry, especially in the field of rare diseases. She also […]
Vaccines and Value Assessment – 7 Updates
Navigating the evaluation requirements from health technology assessment (HTA) agencies and national immunization technical agency groups (NITAGs) is a must for vaccine development. PRMA Consulting has released a series of 7 articles meant to bring health outcomes and economics researchers and […]
NICE’s 5-Year Strategy Signals a More Collaborative Approach.
The UK’s National Institute for Health and Care Excellence (NICE) new health technology assessment manual signals a push towards greater collaboration with the pharmaceutical industry. The new protocol moves away from the previous more oppositional relationship between industry and the agency. […]
What the European Union can Teach the US About Health Technology Assessment Harmonization
Health Technology Assessment (HTA) in the US is a convoluted piecemeal process where each payer performs their own assessments without coordinating with one another, wasting effort and raising costs. In the EU, however, government bodies are responsible for HTA and release pricing and coverage […]
Webinar: Cost-effectiveness of R vs. Excel in Health Technology Assessments
On Wednesday, December 15th at 12:OOPM EST, Jeroen Jansen, Petros Pechlivanoglou, and Howard Thom will present a webinar examining the cost-effectiveness of using the programing language R instead of Excel for health technology assessment (HTA) analysis. While Excel has long been the standard, it […]
Changing Dynamics Between NICE and Pharmaceutical Industry
Recent shifts in the UK’s National Institute for Health and Care Excellence’s (NICE) approach to health technology assessment (HTA) are encouraging a more collaborative relationship with the agency and the pharmaceutical industry. Earlier this year, NICE published their 5-year strategy entitled, […]
HTA Submissions and Single-Arm Trials: An ISPOR EUROPE Panel Presentation
On December 2nd (11 AM to 12 PM), the use of single-arm trials for Health Technology Appraisal (HTA) will be discussed in a panel presentation led by Dr. Bart Heeg, Vice President of Health Economics at Cytel. HTA bodies have begun accepting evidence from single-arm trials, but the heterogeneity of […]
ISPOR Hosts Virtual Middle East and Africa 2021 HTA Roundtable
The International Society for Pharmacoeconomics and Outcomes (ISPOR) hosts regular meetings to discuss the adoption of health technology assessments (HTAs). These HTA Roundtables promote lively interdisciplinary discussions regarding scientific methods, challenges faced by HTAs, and barriers that […]
Comprehensive Literature Review on HTA Applications of Regulatory Sandboxes Now Available
A recent article, published in Applied Health Economics and Health Policy, describes how the regulatory sandbox could impact Health Technology Assessments (HTAs). The authors performed a systematic literature review composed of 46 reports, noting a growing use of sandboxes throughout healthcare, […]
Veradigm Announces Collaboration With CareMetx to Streamline Patient Access to Specialty Medications
Veradigm has announced a new partnership with CarMetx. The collaboration will streamline patient access to specialty medications using Veradigm’s automated platform and improve medication adherence. “Serving pharmaceutical, biotechnology and device manufacturers, CareMetx leverages a digital hub […]
